title: Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial.
authors.affiliation: Probity Medical Research, Waterloo, Ontario, Canada.
authors.forename: Kim A
authors.initials: KA
authors.lastname: Papp
authors.affiliation: Dermatology Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
authors.forename: Cathy
authors.initials: C
authors.lastname: Reid
authors.affiliation: Department of Medicine (Dermatology) and Department of Dermatology, The University of Melbourne, St Vincent's Hospital Melbourne, Melbourne, Victoria and Skin and Cancer Foundation, Carlton, Victoria, Australia.
authors.forename: Peter
authors.initials: P
authors.lastname: Foley
authors.affiliation: Department of Medicine (Dermatology) and Department of Dermatology, The University of Melbourne, St Vincent's Hospital Melbourne, Melbourne, Victoria and Skin and Cancer Foundation, Carlton, Victoria, Australia.
authors.forename: Rod
authors.initials: R
authors.lastname: Sinclair
authors.affiliation: Pharmacokinetics and Drug Metabolism, Amgen, Seattle, Washington, USA.
authors.forename: David H
authors.initials: DH
authors.lastname: Salinger
authors.affiliation: Early Development, Amgen, Thousand Oaks, California, USA.
authors.forename: Gary
authors.initials: G
authors.lastname: Williams
authors.affiliation: Biostatistics, Amgen, South San Francisco, California, USA.
authors.forename: Hua
authors.initials: H
authors.lastname: Dong
authors.affiliation: Rockefeller University, New York, New York, USA.
authors.forename: James G
authors.initials: JG
authors.lastname: Krueger
authors.affiliation: Medical Sciences, Amgen, Seattle, Washington, USA.
authors.forename: Chris B
authors.initials: CB
authors.lastname: Russell
authors.affiliation: Medical Sciences, Amgen, Seattle, Washington, USA. Electronic address: davidm02@amgen.com.
authors.forename: David A
authors.initials: DA
authors.lastname: Martin
mesh_terms: D000328:Adult; D000888:Antibodies, Anti-Idiotypic / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D008875:Middle Aged; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology; D053722:Receptors, Interleukin-17 / Q000276:immunology*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D000888:Antibodies, Anti-Idiotypic; D053722:Receptors, Interleukin-17